Evidence map›Paper›PMID 34411494›Full record

ArticleHuman vaccines & immunotherapeutics2022

Cost of conducting Measles-Rubella vaccination campaign in India.

Susmita Chatterjee, Dayoung Song, Palash Das, Pradeep Haldar, Arindam Ray, Logan Brenzel, Laura Boonstoppel, Vittal Mogasale

Abstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Susmita ChatterjeeDepartment of Research, George Institute for Global Health, New Delhi, India.
Dayoung SongDepartment of Policy and Economic Research, International Vaccine Institute, Seoul, Republic of Korea.
Palash DasDepartment of Research, George Institute for Global Health, New Delhi, India.
Pradeep HaldarImmunization Division, Ministry of Health and Family Welfare, Government of India, New Delhi, India.
Arindam RayBill & Melinda Gates Foundation, New Delhi, India.
Logan BrenzelBill & Melinda Gates Foundation, Seattle, WA, USA.
Laura BoonstoppelThinkWell, USA.
Vittal MogasaleDepartment of Policy and Economic Research, International Vaccine Institute, Seoul, Republic of Korea.ORCID 0000-0003-0596-8072

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A Measles-Rubella (MR) vaccination campaign was launched in India in a phased manner in February 2017 to cover children aged 9 months to 15 years. As evidence on campaign vaccine delivery costs is limited, the delivery cost for MR campaign from a government provider perspective was estimated in four Indian states, namely, Assam, Gujarat, Himachal Pradesh, and Uttar Pradesh. Costs were calculated in top-down and bottom-up approaches using data collected from 84 sites at different administrative levels and immunization partners in the study states from August 2019 to March 2020. All costs were presented in 2019 US$ and Indian Rupee (INR). The financial cost per dose of the MR campaign including all partner support ranged from US$0.16 (INR 10.95) in Uttar Pradesh to US$0.34 (INR 24.13) in Gujarat. In Uttar Pradesh, the full economic cost per dose was US$0.87 (INR 61.39). The key financial cost drivers were incentives related to service delivery and supervision, the printing of reporting formats for record-keeping, social mobilization, and advocacy. The financial delivery cost per dose estimated was higher than the government pre-fixed budget per child for the MR campaign, probably indicating an insufficient budget. However, the study found underutilization of MR budget in two states and use of other sources of funding for the campaign indicating the need for proper utilization of the campaign budgets by the states. Unit cost information generated from this study will be useful for planning, cost projections, and economic analysis of future vaccination campaigns in India.

Indexed as

MeaslesRubellaChildHumansImmunization ProgramsIndiaMeasles VaccineRubella VaccineVaccinationMeasles VaccineRubella Vaccinebudgetdelivery costeconomic analysisIndiaMeaslesRubellavaccination campaign

Identifiers

PMID34411494
PMCPMC8920128

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.